Die adipositasbedingte Insulinresistenz geht mit einer unterschwelligen Entzündungsreaktion einher. Als Antwort auf dieses Entzündungsgeschehen wird PGE2 unter anderem von Kupffer Zellen der Leber freigesetzt und kann seine Wirkung über vier PGE2-Rezeptorsubtypen (EP1-EP4) vermitteln. In vorangegangenen Arbeiten konnte gezeigt werden, dass PGE2 in Rattenhepatozyten über den EP3 R ERK1/2-abhängig die intrazelluläre Weiterleitung des Insulinsignals hemmt. Über die Modulation der Insulinrezeptorsignalkette durch andere EP-Rezeptoren war bisher nichts bekannt. Daher sollte in stabil transfizierten Zelllinien, die jeweils nur einen der vier EP-Rezeptorsubtypen exprimierten, der Einfluss von PGE2 auf die Insulinrezeptorsignalkette untersucht werden. Es wurden HepG2-Zellen, die keinen funktionalen EP-Rezeptor aufwiesen, sowie HepG2-Zellen, die stabil den EP1-R (HepG2-EP1), den EP3β-R (HepG2 EP3β) oder den EP4-R (HepG2 EP4) exprimierten, sowie die humane fötale Hepatozytenzelllinie, Fh hTert, die den EP2- und den EP4-R exprimierte, für die Untersuchungen verwendet. Die Zellen wurden für 330 min mit PGE2 (10 µM) vorinkubiert, um die pathophysiologische Situation nachzustellen und anschließend mit Insulin (10 nM) für 15 min stimuliert. Die insulinabhängige Akt- und ERK1/2-Phosphorylierung wurde im Western-Blot bestimmt. In allen Hepatomzelllinien die EP-R exprimierten, nicht aber in der Zelllinie, die keinen EP R exprimierte, hemmte PGE2 die insulinstimulierte Akt-Phosphorylierung. In allen drei stabil transfizierten Zelllinien, nicht jedoch in den Fh-hTert-Zellen, steigerte PGE2 die basale und insulinstimulierte Phosphorylierung der Serin/Threoninkinase ERK1/2. In den HepG2 EP1- und den HepG2-EP3β-Zellen steigerte PGE2 mutmaßlich über die ERK1/2-Aktivierung die Serinphosphorylierung des IRS, welche die Weiterleitung des Insulinsignals blockiert. Die Hemmung der Aktivierung von ERK1/2 hob in EP3 R-exprimierenden Zellen die Abschwächung der Insulinsignalübertragung teilweise auf. In diesen Zellen scheint die ERK1/2-Aktivierung die größte Bedeutung für die Hemmung der insulinstimulierten Akt-Phosphorylierung zu haben. Da durch die Hemmstoffe die PGE2-abhängige Modulation nicht vollständig aufgehoben wurde, scheinen darüber hinaus aber noch andere Mechanismen zur Modulation beizutragen. In den Fh hTert-Zellen wurde die Insulinrezeptorsignalkette offensichtlich über einen ERK1/2-unabhängigen, bisher nicht identifizierten Weg unterbrochen. Eine gesteigerte PGE2-Bildung im Rahmen der Adipositas ist nicht auf die peripheren Gewebe beschränkt. Auch im Hypothalamus können bei Adipositas Zeichen einer Entzündung nachgewiesen werden, die mit einer gesteigerten PGE2-Bildung einhergehen. Daher wurde das EP R-Profil von primären hypothalamischen Neuronen und neuronalen Modellzelllinien charakterisiert, um zu prüfen, ob PGE2 in hypothalamischen Neuronen die Insulinsignalkette in ähnlicher Weise unterbricht wie in Hepatozyten. In allen neuronalen Zellen hemmte die Vorinkubation mit PGE2 die insulinstimulierte Akt-Phosphorylierung nicht. In der neuronalen hypothalamischen Zelllinie N 41 wirkte PGE2 eher synergistisch mit Insulin. In durch Retinsäure ausdifferenzierten SH SY5Y-Zellen waren die Ergebnisse allerdings widersprüchlich. Dies könnte darauf zurückzuführen sein, dass die Expression der EP Rezeptoren im Verlauf der Kultur stark schwankte und somit die EP R-Ausstattung der Zellen zwischen den Zellversuchen variierte. Auch in den primären hypothalamischen Neuronen variierte die EP R-Expression abhängig vom Differenzierungszustand und PGE2 beeinflusste die insulinstimulierte Akt-Phosphorylierung nicht. Obwohl in allen neuronalen Zellen die Akt-Phosphorylierung durch Insulin gesteigert wurde, konnte in keiner der Zellen eine insulinabhängige Regulation der Expression von Insulinzielgenen (POMC und AgRP) nachgewiesen werden. Das liegt wahrscheinlich an dem niedrigen Differenzierungsgrad der untersuchten Zellen. Im Rahmen der Adipositas kommt es zu einer Überaktivierung des Endocannabinoidsystems. Endocannabinoidrezeptoren sind mit den EP Rezeptoren verwandt. Daher wurde geprüft, ob Endocannabinoide die Insulinsignalweiterleitung in ähnlicher Weise beeinflussen können wie PGE2. Die Vorinkubation der N 41-Zellen für 330 min mit einem Endocannabinoidrezeptoragonisten steigerte die insulinstimulierte Akt-Phosphorylierung, was auf einen insulinsensitiven Effekt von Endocannabinoiden hindeutet. Dies steht im Widerspruch zu der in der Literatur beschriebenen endocannabinoidabhängigen Insulinresistenz, die aber auf indirekte, durch Endocannabinoide ausgelöste Veränderungen zurückzuführen sein könnte. / The obesity related insulin resistance is accompanied by a low grade inflammation. In response to inflammatory stimuli, PGE2 is released from Kupffer cells and signals through four G-Protein coupled PGE2-receptors (EP1-EP4). Previous work showed that PGE2 attenuated insulin signaling in rat hepatocytes through an EP3ß- and ERK1/2-dependent mechanism. Since EP-receptor expression on hepatocytes varies between species and physiological conditions, the effect of the individual EP receptor subtypes on insulin signaling was studied in hepatoma cell lines expressing individual EP receptor subtypes. HepG2 cells lacking functional EP-receptors, and derivatives stably expressing either EP1 receptor (HepG2-EP1), EP3ß receptor (HepG2-EP3ß) or EP4 receptor (HepG2-EP4) and Fh-hTert cells expressing EP2- and EP4-receptor were pre-incubated with PGE2 for 330 min to mimic the sub-acute inflammation. The cells were subsequently stimulated with insulin for 15 min. Akt and ERK1/2 activation was determined by Western Blotting with phospho-specific antibodies. PGE2 inhibited insulin stimulated Akt phosphorylation in all cell lines expressing EP receptors, except in HepG2 cells which are lacking functional EP receptors. PGE2 increased insulin stimulated phosphorylation of the serine/threonine kinase ERK1/2 in all EP R expressing HepG2 cell lines except in Fh-hTert cells. In HepG2-EP1 and HepG2 EP3ß cells PGE2 increased the serine phosphorylation of the insulin receptor substrate, presumably through an ERK1/2 activation. This IRS-serine phosphorylation leads to attenuation of insulin signal transduction. Inhibiting ERK1/2 activation with a specific inhibitor attenuated the PGE2-dependent inhibition of insulin signal transmission in HepG2 EP3ß cells to some extent. ERK1/2 activation in these cells seems to be of major importance for the observed attenuation of insulin stimulated Akt phosphorylation. Application of inhibitors in the other cell lines stably expressing EP receptors provided evidence that other mechanisms contributed to the attenuation of insulin signaling. Insulin signal transduction in Fh-hTert cells by PGE2 was apparently blocked by an ERK1/2-independent mechanism. Increased PGE2 production during obesity is not limited to the periphery. Signs of inflammation have been detected in the hypothalamus, which might be associated with an increased PGE2 production. Therefore, the EP receptor profile of primary neurons as well as neuronal cell models was characterised in order to investigate, whether PGE2 attenuates insulin signal transduction in neuronal cells similar to what was observed in hepatocytes. Pre-incubation with PGE2 did not attenuate insulin stimulated Akt phosphorylation in all neuronal cells. The EP receptor profile in SH SY5Y cells and in primary neurons varied depending on the differentiation status of the cells. Although Akt-kinase was phosphorylated in response to insulin stimulation in all neuronal cells studied, gene expression of insulin target genes (POMC, AgRP) was not modulated by insulin. This might be due to the low level of differentiation of the investigated cells. In the course of obesity, an over-activation of the endocannabinoid system is detected. Since endocannabinoid receptors are related to EP receptors, it was investigated whether endocannabinoids can interfere with insulin signaling in a similar way as PGE2. Pre-incubation of the neuronal cell line N 41 for 330 min with an endocannabinoid receptor agonist, increased insulin stimulated Akt phosphorylation. This implies an insulin sensitising effect of endocannabinoids. This is contradictory to the endocannabinoid-dependent insulin resistance described in the literature and might be caused by indirect endocannabinoid-triggered mechanisms.

Diss. (sammanfattning) Stockholm : Karol. inst., 2003. / Härtill 5 uppsatser.

Prostaglandin (PG) E2 is an eicosanoid derived from the polyunsaturated twenty carbon fatty acid arachidonic acid (AA). PGE2 has physiological as well as pathophysiological functions and is known to be a key mediator of inflammatory responses. Formation of PGE2 is dependent upon the activities of three specific enzymes involved in the AA cascade; phospholipase A2 (PLA2), cyclooxygenase (COX) and PGE synthase (PGEs). Although the research within this field has been intense for decades, the regulatory mechanisms concerning the PGE2 synthesising enzymes are not completely established. PGE2 was investigated in human monocytes with or without lipopolysaccharide (LPS) pre-treatment followed by stimulation with calcium ionophore, opsonised zymosan or phorbol myristate acetate (PMA). Cytosolic PLA2a (cPLA2a) was shown to be pivotal for the mobilization of AA and subsequent formation of PGE2. Although COX-1 was constitutively expressed, monocytes required expression of COX-2 protein in order to convert the mobilized AA into PGH2. The conversion of PGH2 to the final product PGE2 was to a large extent due to the action of microsomal PGEs-1 (mPGEs-1). In addition, experiments with inhibitors of extracellular signal regulated kinase and p38 activation, indicated that phosphorylation of cPLA2α was markedly advantageous for the formation of PGE2. Ellagic acid, a natural polyphenolic compound found in fruits and nuts, was shown to inhibit stimuli induced release of PGE2 in human monocytes. The effect of ellagic acid was not due to a direct effect on the activities of the enzymes but rather to inhibition of the LPS-induced protein expression of COX-2, mPGEs-1 and cPLA2a.

The pathogenesis of inflammatory liver diseases and development of liver fibrosis involves hepatocytes as well as non-parenchymal liver cells like resident liver macrophages (Kupffer cells (KC)), Stellate cells and endothelial cells. Kupffer cells play a critical role in liver (patho)physiology and in the defense of the liver during inflammation. They constitute about 50% of non-parenchymal cells and are the largest population of tissues macrophages in the body. Infections, toxins (lipopolysacharide (LPS)), parenchymal damage and stresses stimulate the inflammatory response of Kupffer cells with the following secretion of bioactive factors, cytotoxicity, antigen processing, etc. Resident liver macrophages are the main producers of inflammatory mediators in the liver. Among them there are prostanoids (prostaglandin (PG) E2 and thromboxane (Tx) A2), cytokines (e.g. interleukin (IL)-1,-6, -10, tumor necrosis factor (TNF) α) and inorganic mediators like nitric oxide (NO). Macrophages-derived products play opposing roles in the development of liver fibrogenesis: IL-1β, TNFα, IL-6, transforming growth factor (TGF)-β and TxA2 (pro-fibrogenic mediators) promote whereas PGE2, IL-10 and nitric oxide (anti-fibrogenic mediators) suppress liver fibrogenesis. The present study shows the production of PGE2 and TxA2 by resident liver macrophages upon prolonged activation by LPS and the characterization of biosynthesis pathways. The production of PGE2 and TxA2 is followed during 24 h after stimulation of macrophages with LPS. The involvement of enzymes is measured on the RNA level (RT-PCR), protein level (Western blot analysis) and activity (activity assays), respectively. The amounts of released prostanoids are measured at time points 2, 4, 8 and 24 h after LPS stimulation. The production of PGE2 is very low without stimulation, shows a delay within the first few hours after stimulation with LPS, and thereafter linearly increases up to 24 h. TxA2 production is very low without stimulation, and increases without a time-delay after the addition of LPS. Prostanoid biosynthesis is inhibited by dexamethasone. The present study shows the involvement and regulation of the AA cascade by the following enzymes: cPLA2: is expressed in resting Kupffer cells; cPLA2 expression and phosphorylation is increased by LPS, dexamethasone suppresses the LPS effect, localization in membrane fraction. COX-1: is expressed in resting Kupffer cells; COX-1 expression is not influenced by LPS and dexamethasone. The COX-1 inhibitor SC560 suppresses the LPS-induced production of PGE2 and TxA2 (8h and 24h), localization predominantly in membrane fraction. COX-2: is almost not expressed in resting Kupffer cells; COX-2 expression is highly increased by LPS, dexamethasone suppresses the LPS effect. The COX-2 inhibitor SC236 inhibits the production of PGE2 and TxA2 at 8h by about 77% and 20%, and at 24h by about 42% and 34%, respectively, localization predominantly in membrane fraction. mPGES-1: is almost not expressed in resting cells; mPGES-1 expression is highly increased by LPS, dexamethasone suppresses the LPS effect, localization in membrane fraction. mPGES-2: is expressed in resting Kupffer cells; mPGES-2 expression is slightly increased by LPS, localization predominantly in membrane fraction. cPGES: is expressed in resting Kupffer cells; LPS has no effect, localization predominantly in soluble fraction. TxA2 synthase: is expressed in resting Kupffer cells; LPS and dexamethasone have no effect, localization predominantly in membrane fraction. Treatment of Kupffer cells with IL-1ß and TNF-α leads to an enhanced release of PGE2 and TxA2 and upregulate the expression of cPLA2, COX-2 and mPGES-1. IL-6 has no effect on prostanoid production. In contrast, IL-10 suppresses the LPS-induced production of PGE2 and TxA2 and expression of cPLA2, COX-2 and mPGES-1. Resting Kupffer cells release very low amounts of NO and do not express iNOS, nNOS and eNOS. LPS, TNF-α and IL-1ß upregulate NO release and the expression of iNOS whereas dexamethasone and IL-10 downregulate NO release and the expression of iNOS. PGE2 suppresses the LPS-induced release of NO but enhances the cytokine-induced release of NO. NO induces a release of PGE2. Thus, the study demonstrates a crosstalk between prostanoids, nitric oxide and cytokines in Kupffer cells under inflammatory conditions and demonstrates a possible anti-fibrogenic effect of PGE2 in the process of liver fibrogenesis.

Microsomal prostaglandin E synthase-1 (mPGES-1) is the terminal enzyme following cyclooxygenase-2 (COX-2) for the production of prostaglandin E₂(PGE₂), and has been identified as a novel therapeutic target for cancers. From an in silico screen aimed at developing novel small molecule inhibitors of mPGES-1, a 2-aminothiazole compound PGE0001 was identified from 13 putative hits based on its ability to reduce cellular PGE₂ and minimal COX-2 inhibition in vitro. Utilizing drug design strategies based on a 4-point pharmacophore model, we also discovered a new series of compounds exhibiting superior potency without inhibiting COX-2, as exemplified by compound PGE0056. In multiple cancer cell lines, both PGE0001 and PGE0056 reduced cytokine-stimulated PGE₂ release with submicromolar EC₅₀ values, although the two compounds exhibited differential kinetics. Importantly, these compounds showed promising anti-tumor effects in xenograft mouse models. Mice injected with the compounds also had reduced PGE₂ in serum. Surprisingly, none of the compounds inhibited mPGES-1 in cell-free assays, except for MK-886, a reported mPGES-1 inhibitor. In order to determine the mechanisms of action of PGE0001 and PGE0056, the PGE₂ synthesis cascade was extensively examined. Immunoblotting analysis suggested that the PGE₂ reduction in a short time frame was not due to alteration of the protein level of enzymes involved in PGE₂ synthesis/metabolism. So far, we have excluded upstream COX-1/2, phospholipase A₂, and other PGE synthases (mPGES-2 & cytosolic PGES) as major targets for PGE0001 or PGE0056. Interestingly, these compounds were found to inhibit a number of kinases implicated in cancer, presumably due to their structural feature. Although these alternative kinase targets may not sufficiently explain the mechanisms responsible for PGE₂ reduction, inhibition of them may strengthen the therapeutic potential of our compounds. We also implemented a target pull-down approach using biotinylated derivatives of these compounds, followed by proteomic analysis to isolate targets to which these compounds bind. As a result, we identified a couple of other enzymes involved in the arachidonic acid metabolic pathway, which need to be further validated. In summary, we identified novel classes of anti-inflammatory compounds with anti-tumor activity, although the mechanisms of action remain to be clarified.

O 17β-E2 estimula a expressão de receptores endometriais, ER e OXTR. A ativação de OXTR induz a ativação da cadeia de síntese de PGF2α. A hipótese do presente estudo é que as enzimas de síntese de PGF2α são reguladas pelo 17β-E2. Objetivou-se determinar os efeitos do 17β-E2 na expressão gênica e proteica, assim como na localização de proteínas envolvidas na síntese de PGF2α. Vacas Nelore multíparas, solteiras e cíclicas foram sincronizadas por aplicação de BE e inserção de dispositivo de P4. Após 8 dias realizou-se a remoção do dispositivo de P4 e aplicação de PGF2α, seguido por 4 dias de observação de estro (D0=dia do estro). Entre D14 e D27 foram realizadas avaliações diárias da área do CL (cm2), fluxo sanguíneo (%) e concentração plasmática de progesterona (P4). No D15 as vacas foram divididas em três grupos: Controle (C; não tratado;N= 10), Placebo (P; 6mL de etanol 50%; IV; N= 21) e Estradiol (E; 3mg 17β-E2; 6mL de etanol 50%; IV;N=21). Subsequente aos tratamentos, biópsias uterinas foram coletadas nos tempos 0h (C; N=10); 4h (E4h, N=11 e P4h; N=10) ou 7h (E7h, N=10 e P7h, N=11). Amostras de sangue foram obtidas nos tempos 0h a 7h, para mensuração das concentrações PGFM no D15. O grupo E apresentou acentuada diminuição da área do CL, fluxo sanguíneo e concentração de P4 (P<0,05), comparado ao grupo P. Comparado ao grupo P, as vacas do grupo E anteciparam o dia da luteólise funcional e estrutural em 2 e 3 dias, respectivamente. O grupo E apresentou maior concentração de PGFM nos tempos 4h, 6h e 7h (P<0,05), comparado ao grupo P. A quantificação dos transcritos realizada por qPCR (N=6/grupo). Na hora 4, a abundância dos genes ESR1, ESR2, PRKCα, PRKCβ, PLA2G4, AKR1B1 e AKR1C4 foi menor nas amostras E4h, enquanto OXTR foi maior nas mesmas amostras comparando-se com as amostras P4h (P<0,05). A expressão gênica de PTGS2 não diferiu entre os grupos E4h e P4h (P>0,05). Na hora 7, as amostras E7h também apresentaram menor abundância de ESR1, PRKCα, PRKCβ, AKR1B1 e AKR1C4 (P<0,05) e houve tendência para menor expressão de ESR2, comparado às amostras P7h. Contudo, não houve diferença na abundância de OXTR, PLA2G4 e PTGS2 entre as amostras E7h e P7h (P>0,05). A abundância da enzima PKCα analisada por Western Blotting (N=3/grupo) foi diminuída tanto nas amostras E4h como nas E7h, em relação às amostras P4h e P7h, respectivamente. Na avaliação por imunohistoquímica (N=5/grupo), o grupo E4h apresentou maior imunomarcação de PGR no epitélio glandular (P< 0,05) e houve tendência para maior imunomarcação de PKCϒ no epitélio luminal, comparado ao grupo P4h (P=0,08). Houve tendência para menor imunomarcação de ERα no epitélio glandular do grupo E4h comparado ao grupo E7h (P=0,1). Concluí-se que a aplicação do 17β-E2 levou a redução da maioria dos transcritos das moléculas de síntese de PGF2α, assim como da abundância de PKCα. O possível mecanismo para a estimulação de PGFM por 17β-E2 pode incluir o aumento da ativação de enzimas que participam na cascata de síntese de PGF2α. / 17β-E2 stimulates the expression of endometrial receptors, ER and OXTR. Activation of OXTR induces the activation of the synthesis of PGF2α pathway. The central hypothesis is that the enzymes involved in PGF2 synthesis are reguleted by 17β-E2. The objective of this study was to determine the effects of 17β-E2 on gene and protein expression and localization of the enzymes involved in PGF2α synthesis. Multiparous, non-lactating and cyclic Nelore cows were synchronized by BE application and P4 device insertion. After 8 days the P4 device was removed and a single dose of PGF2α applied, followed by 4 days of estrus detection (D0 = day of estrus). Daily measurements of CL area (cm2), blood flow (%), and plasma progesterone concentration (P4) were performed between D14 and D27. On D15 cows were divided into three groups: Control (C, untreated, N = 10), Placebo (P; 6mL of ethanol 50%, IV; N = 21) and Estradiol (E; 3mg 17β-E2; Ethanol 50%, IR: N = 21). After the treatments administration, uterine biopsies were collected at times 0h (C; N = 10); 4h (E4h, N = 11 and P4h, N = 10) or 7h (E7h, N = 10 and P7h, N = 11). Blood samples were obtained from time 0h to 7h for the measurement of the PGFM concentrations on D15. Group E showed a marked decrease in CL area, blood flow, and P4 concentration (P <0.05) compared to group P. Also, when compared to group P, cows from group E anticipated the day of functional and structural luteolysis in 2 and 3 days, respectively. Group E presented higher concentration of PGFM at 4h, 6h and 7h (P <0.05), compared to group P. The transcripts abundance was performed by qPCR (N = 6 / group). The transcripts abundance of ESR1, ESR2, PRKCα, PRKCβ, PLA2G4, AKR1B1, and AKR1C4 genes was lower in the E4h samples, while OXTR was higher in the same samples compared to the P4h (P <0.05) samples in the time 4h. The gene expression of PTGS2 did not differ between groups E4h and P4h (P> 0.05). At time 7h, samples E7h also had lower abundance of ESR1, PRKCα, PRKCβ, AKR1B1 and AKR1C4 (P <0.05) and there was a tendency for lower ESR2 expression, compared to samples P7h. Nevertheless, there was no difference in the abundance of OXTR, PLA2G4, and PTGS2 between samples E7h and P7h (P> 0.05). The abundance of the PKCα enzyme analyzed by Western Blotting (N = 3 / group) was decreased in both the E4h and E7h samples, relative to the samples P4h and P7h, respectively. In the evaluation by immunohistochemistry (N = 5 / group), the E4h group presented greater PGR immunostaining in the glandular epithelium (P <0.05) and there was a tendency for a greater immunostaining of PKCϒ in the luminal epithelium, compared to the P4h group (P = 0,08). There was a tendency for lower ERα immunostaining in the glandular epithelium of the E4h group compared to the E7h group (P = 0.1). It was concluded that the application of 17β-E2 led to the reduction of most of the transcripts of the PGF2α synthesis molecules, as well as the abundance of PKCα. The possible mechanism for stimulation of PGFM by 17β-E2 may include increased activation of enzymes that participate in the cascade of PGF2α synthesis.

Apesar de inúmeros estudos desenvolvidos no Brasil e no mundo, a utilização das biotecnologias de superovulação (SOV) e transferência de embriões (TE) em bubalinos ainda apresenta resultados inconsistentes, associados à principalmente à baixa taxa de recuperação de embriões. Dessa forma, o objetivo do presente estudo foi avaliar o efeito da utilização de dispositivo de P4 (para promover diminuição da contratilidade do trato genital, Capitulo 1) ou da administração de PGF2&#945; (para promover aumento da atividade da fímbria e da frequência do batimento ciliar, Capítulo 2) durante o período periovulatório na captação dos oócitos pelas fímbrias e no aumento da produção de embriões em búfalas superovuladas. No Experimento 1 (Capítulo 1), doadoras bubalinas foram homogeneamente divididas em dois grupos: controle (G-C; n=8) e tratamento com progesterona (P4) durante o período periovulatório (G-P4; n=8). A emergência da onda de crescimento folicular foi sincronizada com um dispositivo intravaginal de P4 e a administração de 2 mg i.m. de benzoato de em dia aleatório do ciclo estral (Dia 0; D0). A partir do D4, todas as búfalas receberam 200 mg i.m. de FSH duas vezes ao dia, em 8 doses decrescentes. Foram administrados 530&micro;g i.m. de PGF2&#945; no D6 e no D7. A P4 foi removida do G-C no D7 e do G-P4 no D10. No D8, todas as búfalas receberam 25 mg i.m. de pLH. As inseminações foram realizadas 12 e 24 h após o tratamento com pLH. Foram realizadas colheitas de sangue a cada 12h do D7 ao D11 para posterior dosagem de progesterona. As estruturas embrionárias (oócitos/embriões) foram coletadas pelo método não cirúrgico de lavagem uterina seis dias após a segunda IA (D14). Avaliações ultrassonográficas dos ovários foram realizadas no D8 e no D14 para aferir respectivamente as respostas superestimulatória e superovulatória. As variáveis foram analisadas pelo procedimento GLIMMIX do SAS®. As búfalas do G-P4 apresentaram menor taxa de ovulação (13,5±4,9 vs. 71,5±16,1%; P=0,002) e, consequentemente, maior taxa de folículos &ge; 8 mm (87,8±10,6 vs. 34,3±9,8 %; P=0,06) e menor número de CLs no D14 (1,1±0,3 vs. 8,0±2,8; P=0,04) que as búfalas do G-C. O número de estruturas embrionárias (1,9±0,7 vs. 0,0±0,0; P=0,03), de embriões transferíveis (1,6±0,7 vs. 0,0±0,0; P=0,04) e congeláveis (1,6±0,7 vs. 0,0±0,0; P=0,04) foram inferiores para o G-P4. A concentração sérica de progesterona foi maior nos animais do G-P4 (1,87±0,13) que nos do G-C (0,48±0,10; P<0,0001). No Experimento 1 (Capítulo 2), as doadoras foram divididas aleatoriamente em 2 grupos: controle (G-C; n=22) e tratamento com prostaglandina F2&#945; durante o período periovulatório (G-PGF; n=22). Os animais do G-C foram submetidos ao protocolo de superovulação descrito no capítulo 1. No G-PGF todas as búfalas receberam protocolo de superovulação semelhante ao G-C e, adicionalmente, receberam quatro doses de PGF2&#945; (0,53 mg i.m. de cloprostenol sódico) do D8 ao D10 com intervalo de 12h. Foi verificado maior número de estruturas embrionárias recuperadas em búfalas superovuladas tratadas com PGF2&#945; durante o período periovulatório (G-PGF=3,5±0,6) comparado ao grupo controle (G-C=2,3±0,5; P=0,02). Além disso, houve aumento no número de embriões transferíveis (G-PGF=2,7±0,6 vs. G-C=1,8±0,5; P=0,05). No Experimento 2 (Capítulo 2), os animais foram divididos aleatoriamente em três grupos experimentais: Grupo Controle (GC; n=22), Grupo PGF injetável (G-PGF-INJ; n=22) e Grupo PGF Bomba Osmótica (G-PGF-BO; n=22). Os animais pertencentes aos grupos: G-C e G-PGF-INJ foram submetidos aos mesmos protocolos descritos para seus grupos correspondentes no Experimento 1 (Capítulo 2). No GPGF- BO, todas as búfalas receberam protocolo de superovulação semelhante ao G-C e, adicionalmente, receberam a partir do D8 a inserção subcutânea de uma mini-bomba osmótica, contendo PGF2&#945; (2,12 mg de Cloprostenol sódico). A bomba osmótica retirada no D10. Não foram verificadas diferenças no número de estruturas totais recuperadas nas búfalas tratadas com PGF&#945; durante o período periovulatório (G-C=2,1±0,8 vs. G-PGF-INJ=2,1±0,6 vs. GPGF- BO=1,4±0,4; P=0,58). Os tratamentos no período periovulatório com dispositivo intravaginal de P4 (Capítulo 1) e com PGF2&#945; (Capítulo 2) não foram eficientes em aumentar a recuperação de estruturas embrionárias de búfalas superovuladas. / Despite numerous studies conducted in Brazil and world-wide, the use of superovulation (SOV) and embryo transfer (ET) biotechnologies in buffaloes still shows inconsistent results, particularly in terms of low embryos recovery rate. Thus, the aim of this study was to evaluate the use of a P4 device (to decrease contractility of the genital tract, Chapter 1) or PGF2&alpha; administration (to increase activity of the fimbriae and ciliary beat frequency, Chapter 2) during the periovulatory period in the uptake of oocytes by fimbriae and in the increase of embryo production in superovulated buffaloes. In Experiment 1 (Chapter 1), buffalo donors were homogeneously assigned into 2 groups: Control (C-G; n=8) and progesterone (P4) treatment during the periovulatory period (P4-G; n=8). Follicular growth wave emergence was synchronized with an intravaginal P4 device and the injection of 2 mg i.m. of estradiol benzoate at random stage of the estrous cycle (Day 0; D0). From D4 on, all buffaloes received 200 mg i.m. of FSH twice-daily, in 8 decreasing doses. A dose of PGF2&alpha; was given on D6 PM and on D7. The P4 was removed from the C-G on D7 and from the P4-G on D10. On D8, all buffaloes received 25 mg i.m. of pLH. Inseminations were done 12 and 24 h after the pLH treatment. Blood samples were collected every 12h from D7 to D11 for further progesterone assay. The embryonic structures (ova/embryos) were collected by nonsurgical uterine flush 6 days after the second timed AI (D14). Ovarian ultrasound examinations were performed on D8 and on D14 to verify respectively the superestimulation and the superovulatory response. Variables were analyzed by GLIMMIX procedure of SAS®. Buffaloes from P4-G showed lower ovulation rate (13.5±4.9 vs. 71.5±16.1%; P=0.002) and, consequently, higher follicles &ge; 8 mm rate (87.8±10.6 vs. 34.3±9.8 %; P=0.06) and lower number of CLs on D14 (1.1±0.3 vs. 8.0±2.8; P=0.04) than buffaloes from C-G. The total number of embryonic structures (1.9±0.7 vs. 0.0±0.0; P=0.03), transferable (1.6±0.7 vs. 0.0±0.0; P=0.04) and freezable embryos (1.6±0.7 vs. 0.0±0.0; P=0.04) were lower for P4-G. The serum progesterone concentration was greater for animals in P4-G (1.87±0.13) than in the C-G (0.48±0.10; P<0.0001). In Experiment 1 (Chapter 2), donors were randomly assigned into two groups: control (C-G; n=22) and prostaglandin F2&alpha; treatment during the periovulatory period (G-PGF; n=22). Animals from C-G were subjected to the superovulation protocol described on chapter 1. In G-PGF all buffaloes received similar superovulation protocol from the C-G and, additionally, received four doses of PGF2&alpha; (0.53 mg i.m. of sodic cloprostenol) from D8 to D10, 12h apart. A greater number of embryonic structures were recovered from superovulated buffaloes treated with PGF2&alpha; during the periovulatory period (PGF-G=3.5±0.6) compared to control group (C-G=2.3±0.5; P=0.02). Furthermore, increased number of transferable embryos were found in treated animals (PGF-G=2.7±0.6 vs. C-G=1.8±0.5; P=0.05). In Experiment 2 (Chapter 2), animals were randomly assigned into three experimental groups: Control group (CG; n=22), Injectable PGF group (INJ-PGF-G; n=22) and Osmotic pump PGF group (BO-PGF-G; n=22). The animals from C-G and INJ-PGF-G group were subjected to the same protocols described for their correspondent groups in Experiment 1 (Chapter 2). In BO-PGF-G, all buffaloes received the superovulation protocol similar to C-G and, additionally, received from D8, a subcutaneous insertion of a mini osmotic pump, containing PGF2&alpha; (2.12 mg de sodic cloprostenol). The osmotic pump was removed on D10. No differences were found on the total number of recovered structures in buffaloes treated with PGF2&alpha; during the periovulatory period (C-G=2.1±0.8 vs. INJ-PGF-G=2.1±0.6 vs. BO-PGF-G=1.4±0.4; P=0.58). Treatments on the peri- ovulatory period with intravaginal P4 device (Chapter 1) and PGF2&alpha; (Chapter 2) were not efficient in increasing the recovery of embryonic structures in superovulated buffalo.

A fagocitose de células apoptóticas, também denominada eferocitose, é um processo dinâmico e de fundamental importância para homeostase dos tecidos após uma injúria. Estudos demonstraram previamente que a fagocitose de células apoptóticas promove a síntese de mediadores anti-inflamatórios como PGE2, TGF-? e IL-10, podendo resultar num microambiente supressor e aumento da susceptibilidade do hospedeiro contra agentes infecciosos. Entretanto, a fagocitose de células apoptóticas infectadas por células dendríticas promove a geração não apenas de citocinas anti-inflamatórias como TGF-?, mas também de IL-6 e IL-23, levando a um efeito imunoestimulador, a diferenciação de células Th17. A atuação da PGE2 na imunidade adaptativa vem sendo investigada quanto à diferenciação e ativação de linfócitos Th1, Treg e Th17. Nossos resultados demonstram que a fagocitose de células apoptóticas infectadas com E. coli promove a ativação e migração de células dendríticas, assim como a produção de citocinas pró- e anti-inflamatórias e altos níveis de PGE2. No entanto, diferente da hipótese inicial, a presença de altas concentrações de PGE2 inibe drasticamente a diferenciação de células Th17 no contexto de fagocitose de células apoptóticas infectadas com E. coli por células dendríticas, in vitro. O tratamento de linfócitos T CD4+naive com antagonistas e agonistas de EP2/EP4 demonstram que o efeito supressor de PGE2 é mediado primordialmente pelo receptor EP4. Por fim, nossos resultados in vivo comprovam os resultados obtidos in vitro, demonstrando o papel supressor de PGE2 na diferenciação de células Th17 no contexto de fagocitose de células apoptóticas infectadas em modelo de infecção pulmonar. / The phagocytosis of apoptotic cells, also called efferocytosis, is a dynamic process critical for tissue homeostasis after injury. We and other groups previously have shown that phagocytosis of apoptotic cells promotes the synthesis of anti-inflammatory mediators such as PGE2, TGF-? and IL-10, that may result in the suppression of host defense against microorganisms. However, an elegant study using infected apoptotic cells showed that phagocytosis of these cells promote not only the generation of anti-inflammatory cytokines such as TGF-? but also IL-6 and IL-23, resulting in an immunostimulatory effect, the differentiation of Th17 cells. The role of PGE2 in adaptive immunity has been investigated regarding differentiation and activation of Th1, Th17 and Treg. Our results demonstrate that engulfment of E.coli infected apoptotic cells promotes the activation and migration of dendritic cells as well as production of pro and anti-inflammatory cytokines together with high levels of PGE2. However, differing from our hypothesis, high levels of PGE2 inhibits drastically the differentiation of Th17 cells on the context of engulfment of E.coli infected apoptotic cells by dendritic cells in vitro. The treatment of T CD4+naive cells with antagonist or agonists of EP2/EP4 receptors demonstrates the suppressor effect is mainly mediated by EP4 receptor. Finally, the instillation of E.coli infected apoptotic cells in E.coli infected animals resulted on modest Th17 increase but treatment with cox inhibitor increased Th17 cell differentiation. Therefore, our in vivo results prove the in vitro results.

Nas éguas cíclicas, a luteólise ocorre entre os dias 14 e 16 após ovulação, pela ação da PGF2&#940 endometrial. Entretanto, durante a gestação, a luteólise deve ser bloqueada, ao mesmo passo que a ação da PGE2 deve ser estimulada. Ambos hormônios possuem baixa difusão pela membrana plasmática, sendo necessária a presença da proteína transportadora de prostaglandina (PGT) para o influxo e efluxo destes hormônios nas células. Os objetivos deste experimento foram identificar e relacionar o RNAm da PGT no endométrio de éguas cíclica e gestante aos 14 dias (experimento 1) e avaliar o perfil do RNAm para PGT no endométrio eqüino em final de diestro sob efeito de secreção embrionária (experimento 2). Para o experimento 1, um ciclo estral de 11 éguas foi acompanhado. Seis éguas não foram inseminadas e somente detectado o tempo de ovulação e cinco foram inseminadas. Biópsias endometriais foram realizadas quando detectado folículo pré-ovulatório (&#8805;35mm de diâmetro) e edema endometrial (E0; n=6), sete (E7; n=6) e quatorze (E14; n=6) dias após ovulação nas fêmeas cíclicas e aos quatorze dias de gestação (EG; n=4) nas fêmeas gestantes. No experimento 2, 5 embriões eqüinos de 13,5 dias de idade foram coletados, cultivados por 24 horas em ambiente com temperatura e CO2 controlados e o meio condicionado embrionário (MCEE) gerado foi armazenado a -80&ordm;C. Em seguida, amostras endometriais de sete éguas cíclicas aos 14 dias pós ovulação foram coletadas por biópsia uterina e cultivadas por 24 horas, em ambiente com temperatura e CO2 controlados, na presença do MCEE. O RNA total foi extraído de todas as amostras endometriais e amplificado pela reação em cadeia da polimerase em tempo real (RT-PCR), de um passo. A abundância relativa média dos transcritos foi submetida a análise de variância e as médias foram separadas pelo teste LSD (P<0,05). No experimento 1, o RNAm da PGT em tecido equino foi identificado, de maneira que as quantidades relativas deste gene foram similares entre E0, E7, E14 e EG. No experimento 2, o MCEE não modificou a quantidade de RNAm para PGT no endométrio em fase final do diestro. / In cyclic mares, luteolysis occurs between the 14th and 16th days after ovulation, due to endometrial PGF2&#940 However, in pregnant mares luteolysis must be blocked, whereas the PGE2 action must be stimulated. Both hormones have low diffusion through the plasma membrane, wherein the Prostaglandin Transporter Protein (PGT) is needed to influx and efflux of these hormones in the cells. The objectives of this experiment are to identify and to relate with the mRNA to PGT in the endometrium of cyclic and pregnant mares (experiment 1) and to evaluate the mRNA profile to PGT in equine endometrium at end of diestrous, under embryonic secretion effect (experiment 2). In the experiment 1, one estrous cycle of 11 mares (5 to 12 years old) was examined. Six mares were not inseminated and only the time of ovulation was recorded, and five mares were inseminated. Endometrial biopsies were performed when pre-ovulatory follicles (diameter &#8805; 35mm) and endometrial edema were detected (E0; n=6), seven (E7; n=6) and fourteen days (E14; n=6) after ovulation in cyclic mares, and fourteen days after ovulation in pregnant mares (EG; n=4). In the experiment 2, five embryos of 13,5 days of age were collected, cultured during 24 hours in controlled temperature and CO2 and the embrionic conditioned medium (ECM) was stored at -80&ordm;C. After that, endometrium samples of 7 mares at fourteen days after ovulation were collected by uterine biopsy and they were cultured during 24 hours, in controlled temperature and CO2, with ECM. Total RNA was extracted and submitted to amplification by one step real-time polymerase chain reaction (RT-PCR). The abundance relative average of trancripts was submitted to variance analysis and averages were separated by LSD test (P<0,05). In the experiment 1 the mRNA to equine PGT was identified so that the relative quantities of this gene were equal among E0, E7, E14 e EG. In the experiment 2, the ECM did not modify the mRNA quantity to PGT in the endometrium at end of diestrous.

by Wai-keung Leung. / Thesis (M.D.)--Chinese University of Hong Kong, 2001. / Includes bibliographical references (p. 217-232). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web.